Celyad Oncology (Germany) Today
| 1C0 Stock | EUR 0.67 0.01 1.52% |
Performance10 of 100
| Odds Of DistressLess than 30
|
Celyad Oncology is trading at 0.67 as of the 13th of December 2024. This is a 1.52% up since the beginning of the trading day. The stock's lowest day price was 0.67. Celyad Oncology has about a 30 percent probability of financial distress in the next few years of operation but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 24th of December 2022 and ending today, the 13th of December 2024. Click here to learn more.
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of hematological malignancies and solid tumors. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium. The company has 11.94 M outstanding shares. More on Celyad Oncology SA
Moving against Celyad Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Celyad Oncology SA Risk Profiles
Although Celyad Oncology's alpha and beta are two of the key measurements used to evaluate Celyad Oncology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 11.92 | |||
| Semi Deviation | 7.41 | |||
| Standard Deviation | 37.6 | |||
| Variance | 1413.54 |
Celyad Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Celyad Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Celyad Oncology Corporate Management
Elected by the shareholders, the Celyad Oncology's board of directors comprises two types of representatives: Celyad Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celyad. The board's role is to monitor Celyad Oncology's management team and ensure that shareholders' interests are well served. Celyad Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celyad Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hannes Iserentant | Head Property | Profile | |
| Frdric Lehmann | VP Affairs | Profile | |
| David Georges | VP Admin | Profile | |
| MD MBChB | Chief Officer | Profile | |
| Sara Zelkovic | Communications Director | Profile | |
| Philippe Nobels | Chief HR | Profile | |
| BME MBA | CFO, CoFounder | Profile |
Other Information on Investing in Celyad Stock
Celyad Oncology financial ratios help investors to determine whether Celyad Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celyad with respect to the benefits of owning Celyad Oncology security.